• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Large owner Red Sky Ventures Llc converted options into 2,169,420 shares (SEC Form 4)

    6/25/24 10:07:03 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology
    Get the next $TEM alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Red Sky Ventures LLC

    (Last) (First) (Middle)
    1001 GREENBAY ROAD
    SUITE 146

    (Street)
    WINNETKA IL 60093

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Tempus AI, Inc. [ TEM ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/17/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Class A Common Stock 06/17/2024 C 2,169,420 A (1) 16,560,249(3) D(2)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Series A Preferred Stock (1) 06/17/2024 C 1,109,190 (1) (1) Class A Common Stock 1,109,190 $0 0 D(2)
    Series B-1 Preferred Stock (1) 06/17/2024 C 499,965 (1) (1) Class A Common Stock 499,965 $0 0 D(2)
    Series B-2 Preferred Stock (1) 06/17/2024 C 166,718 (1) (1) Class A Common Stock 166,718 $0 0 D(2)
    Series C Preferred Stock (1) 06/17/2024 C 314,338 (1) (1) Class A Common Stock 314,338 $0 0 D(2)
    Series D Preferred Stock (1) 06/17/2024 C 63,652 (1) (1) Class A Common Stock 63,652 $0 0 D(2)
    Series G Preferred Stock (1) 06/17/2024 C 15,557 (1) (1) Class A Common Stock 15,557 $0 0 D(2)
    1. Name and Address of Reporting Person*
    Red Sky Ventures LLC

    (Last) (First) (Middle)
    1001 GREENBAY ROAD
    SUITE 146

    (Street)
    WINNETKA IL 60093

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Keywell Kimberly Jo

    (Last) (First) (Middle)
    1001 GREENBAY ROAD
    SUITE 146

    (Street)
    WINNETKA IL 60093

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    Explanation of Responses:
    1. Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series B-2 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series G Preferred Stock (collectively, the "Preferred Stock") was convertible at any time, at the holder's election, into Class A Common Stock, on a one-for-one basis, had no expiration date and automatically converted into shares of Class A Common Stock upon the closing of the Issuer's initial public offering.
    2. Shares held directly by Red Sky Ventures LLC ("Red Sky"). Kimberly Keywell is the controlling shareholder of Red Sky, may therefore be deemed to have shared voting, investment and dispositive power with respect to the shares held by Red Sky, and disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein.
    3. This amount includes an additional 15,829 shares acquired by the Reporting Persons on June 17, 2024 in connection with the conversion of the Preferred Stock into Class A Common Stock upon the closing of the Issuer's initial public offering, pursuant to which the Issuer paid accrued and unpaid dividends on such shares of Preferred Stock in shares of Class A Common Stock. The issuance of such shares of Class A Common Stock qualifies for the exemption from Section 16 of the Securities Exchange Act pursuant to Rule 16a-9.
    Red Sky Ventures LLC, By: /s/ Kimberly J. Keywell, President 06/25/2024
    /s/ Kimberly J. Keywell 06/25/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $TEM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TEM

    DatePrice TargetRatingAnalyst
    12/2/2025$85.00Overweight
    Morgan Stanley
    10/21/2025$88.00Buy → Hold
    TD Cowen
    10/20/2025$110.00Buy
    Canaccord Genuity
    9/2/2025$90.00Buy
    H.C. Wainwright
    4/21/2025$60.00Buy
    BTIG Research
    2/25/2025$50.00 → $55.00Overweight → Neutral
    Analyst
    2/12/2025Outperform → Mkt Perform
    William Blair
    2/5/2025$58.00 → $74.00Buy
    TD Cowen
    More analyst ratings

    $TEM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Tempus Ai, Inc. bought $2,739,181 worth of shares (320,267 units at $8.55), increasing direct ownership by 3% to 13,039,067 units (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Reporting)

    2/13/26 5:24:46 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Large owner Tempus Ai, Inc. exercised 9,218,800 in-the-money shares at a strike of $2.00 and bought $17,745,000 worth of shares (3,500,000 units at $5.07) (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Reporting)

    8/20/24 4:17:55 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tempus Announces Collaboration with Median Technologies to Integrate AI-Powered Lung Cancer Screening into the Pixel Platform

    Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a collaboration with Median Technologies (EPA: ALMDT) to bring Median's proprietary eyonis® LCS to the Tempus Pixel platform. This collaboration empowers clinical workflows with a powerful tool to support informed diagnostic and disease management decisions. According to a study by the American Cancer Society, only about 20% of eligible individuals in the U.S. were screened for lung cancer in 2024. Closing the gap and achieving full participation among eligible individuals could prevent an estimated 62,110 lung cancer deaths over five years. eyonis® LCS is an AI-bas

    2/12/26 4:05:00 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Median Technologies Announces Collaboration With Tempus to Expand Access to eyonis® LCS Software as a Medical Device in the United States

    The collaboration follows FDA 510(k) clearance for eyonis® LCS and aims to integrate high-performance lung cancer screening detection and diagnosis device into the clinical workflow through the Tempus Pixel platform. Regulatory News: Median Technologies (FR0011049824, ALMDT, "Median" or the "Company"), developer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a provider of AI-enhanced and central imaging services for oncology drug developers, today announced its non-exclusive distribution agreement with Tempus AI, Inc. (NASDAQ:TEM) a technology company leading the adoption of AI to advance precision medicine

    2/12/26 4:05:00 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus to Report Fourth Quarter and Full Year 2025 Financial Results on February 24

    Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the fourth quarter and full year 2025 on Tuesday, February 24, 2026. The company will hold the earnings conference call at 4:30 pm ET. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 4652845 United States - New York: (646) 307-1963 USA & Canada - Toll-Free: (800) 715-9871 Live Webcast: https://edge.media-

    2/10/26 8:30:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Tempus Ai, Inc. bought $2,739,181 worth of shares (320,267 units at $8.55), increasing direct ownership by 3% to 13,039,067 units (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Reporting)

    2/13/26 5:24:46 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Director Epstein David R sold $21,982 worth of shares (370 units at $59.41), decreasing direct ownership by 1% to 26,051 units (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Issuer)

    2/4/26 4:30:12 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    CEO and Chairman Lefkofsky Eric P sold $10,899,207 worth of shares (166,250 units at $65.56) (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Issuer)

    1/30/26 4:15:08 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Tempus AI Inc.

    SCHEDULE 13G/A - Tempus AI, Inc. (0001717115) (Subject)

    2/10/26 5:10:29 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    SEC Form 144 filed by Tempus AI Inc.

    144 - Tempus AI, Inc. (0001717115) (Subject)

    1/28/26 4:21:30 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus AI Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure

    8-K - Tempus AI, Inc. (0001717115) (Filer)

    1/12/26 6:05:18 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley resumed coverage on Tempus AI with a new price target

    Morgan Stanley resumed coverage of Tempus AI with a rating of Overweight and set a new price target of $85.00

    12/2/25 8:35:17 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus AI downgraded by TD Cowen with a new price target

    TD Cowen downgraded Tempus AI from Buy to Hold and set a new price target of $88.00

    10/21/25 7:15:53 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Canaccord Genuity initiated coverage on Tempus AI with a new price target

    Canaccord Genuity initiated coverage of Tempus AI with a rating of Buy and set a new price target of $110.00

    10/20/25 8:04:09 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Leadership Updates

    Live Leadership Updates

    View All

    Tempus Announces Six Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer Annual Meeting 2025

    Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that six abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025. The meeting is taking place November 5 - 9 at the Gaylord National Convention Center in National Harbor, Maryland. "We're excited to join the oncology community at this year's meeting and highlight our latest research and progress in advancing the immuno-oncology field," said Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus. "Our latest findings demonstrate the potential of integrated, data-driven approaches to refine biomarkers, im

    11/5/25 8:30:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Tempus AI Inc.

    SC 13G - Tempus AI, Inc. (0001717115) (Subject)

    11/12/24 5:00:02 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    SEC Form SC 13G filed by Tempus AI Inc.

    SC 13G - Tempus AI, Inc. (0001717115) (Subject)

    11/12/24 4:30:28 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Amendment: SEC Form SC 13D/A filed by Tempus AI Inc.

    SC 13D/A - Tempus AI, Inc. (0001717115) (Filed by)

    8/20/24 4:27:51 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Financials

    Live finance-specific insights

    View All

    Tempus to Report Fourth Quarter and Full Year 2025 Financial Results on February 24

    Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the fourth quarter and full year 2025 on Tuesday, February 24, 2026. The company will hold the earnings conference call at 4:30 pm ET. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 4652845 United States - New York: (646) 307-1963 USA & Canada - Toll-Free: (800) 715-9871 Live Webcast: https://edge.media-

    2/10/26 8:30:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus to Report Third Quarter 2025 Financial Results on November 4

    Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter of 2025 on November 4, 2025. The company will hold the earnings conference call at 4:30 pm ET. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 5436492 USA & Canada: Toll-Free (800) 715-9871 United States: Toll (646) 307-1963 Live Webcast: https://edge.media-server.com/mmc/p/vg3azega A

    10/21/25 8:30:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus Announces the Acquisition of Paige

    Paige's strong foundation in pathology and AI is rooted in its proprietary dataset of almost 7 million digitized pathology slides that are clinically annotated Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the acquisition of Paige, an AI company specializing in digital pathology. The acquisition allows Tempus to grow its dataset, expand its experienced technical team, and establish a strong footprint in digital pathology with an industry leading technology portfolio. Founded in 2017, Paige has developed and deployed several AI applications, including the first FDA-cleared AI application in pathology, allowin

    8/22/25 9:20:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology